Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Department of Paediatrics, University of Sumatera Utara, Medan, Indonesia.
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.02539-19.
Artemisinin-based combination therapy (ACT) is the first-line antimalarial regimen in Indonesia. Susceptibility of to artemisinin is falling in the Greater Mekong subregion, but it is not known whether the efficacy of current combinations is also threatened in nearby Sumatera. We evaluated the genetic loci , and , considered to be under selection by artemisinin combination therapy, among 404 infections identified by PCR detection in a cross-sectional survey of 3,731 residents of three regencies. The haplotype SVMNT (codons 72 to 76) was the most prevalent and displayed significant linkage disequilibrium with the haplotype YY (codons 86 and 184) (odds ratio [OR] 26.7; 95% confidence interval [CI], 5.96 to 239.4; 0.001). This contrasts with Mekong countries, where the CVIET haplotype of predominates. Among 231 evaluable isolates, only 9 (3.9%) showed any evidence of nonsynonymous gene variants in the propeller domain of The Thr474Ala variant was seen in six individuals, and Cys580Tyr was identified with low confidence in only a single isolate from an asymptomatic individual. Among a subset of 117 symptomatic -infected individuals randomized to receive either dihydroartemisinin-piperaquine or artemether-lumefantrine, the treatment outcome was not associated with pretreatment genotype. However, submicroscopic persistent parasites at day 28 or day 42 of follow-up were significantly more likely to harbor the haplotype NF (codons 86 and 184) than were pretreatment isolates ( < 0.001 for both treatment groups). Current ACT regimens appear to be effective in Sumatera, but evidence of persistent submicroscopic infection in some patients suggests further detailed studies of drug susceptibility should be undertaken.
基于青蒿素的联合疗法 (ACT) 是印度尼西亚的一线抗疟方案。在大湄公河次区域,青蒿素的敏感性正在下降,但尚不清楚附近苏门答腊的现有联合疗法的疗效是否也受到威胁。我们评估了 404 例通过 PCR 检测鉴定的 感染患者的遗传基因座 、 和 ,这些基因座被认为是由青蒿素联合疗法选择的。这些患者来自三个县的 3731 名居民的横断面调查。SVMNT 单倍型(密码子 72 至 76)最为普遍,与 86 和 184 密码子的 YY 单倍型(OR 26.7;95%置信区间 [CI],5.96 至 239.4;0.001)显著连锁不平衡。这与湄公河国家形成鲜明对比,在那里, 主要表现为 CVIET 单倍型。在 231 例可评估的分离株中,只有 9 例(3.9%)在 螺旋桨结构域中显示出任何非同义基因突变的证据。在 6 名个体中观察到 Thr474Ala 变异,在仅从无症状个体中分离出的单个分离株中低置信度地鉴定出 Cys580Tyr。在随机分配接受二氢青蒿素-哌喹或青蒿琥酯-咯萘啶的 117 例有症状 -感染个体亚组中,治疗结果与预处理基因型无关。然而,在随访第 28 天或第 42 天仍存在亚微观持续寄生虫的个体中,携带 NF 单倍型(86 和 184 密码子)的可能性显著高于预处理分离株(两组均 <0.001)。目前的 ACT 方案在苏门答腊似乎有效,但一些患者存在持续的亚微观感染的证据表明,应进一步进行药物敏感性的详细研究。